Adipokines - Targeting a root cause of cardiometabolic risk

QJM: An International Journal of Medicine

Volumn 101, Issue 10, 2008, Pages 767-776

  Bakhai, Ameet ^a  

^a BARNET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSINOGEN; BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN; VISFATIN;

ABNORMAL FECES; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEFECATION URGENCY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EXERCISE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION;

EID: 53049100693     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn066     Document Type: Review

References (87)

1. Deaths by Cause, Sex and Age, 2004, United Kingdom. 2006. [http://www.heartstats.org/temp/Tabsp1.2spweb06.xls] Last accessed 8th January 2008.
2. Despres JP. Health consequences of visceral obesity. Ann Med 2001; 33:534-41.
3. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al., Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-6.
4. Trayhum P, Wood IS. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347-55.
5. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. Br Med J 2001; 322 716-20.
6. Bjomtorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10 493-6.
7. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13:4539-50.
8. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
9. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972-8.
10. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27(Suppl 3):S53-5.
11. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91:2755-60.
12. Yudkin J, Kumari M, Humphries S, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000; 148:209-14.
13. Koenig W, Sund M, Frohlich M, Fischer H-G, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-42.
14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347 1557-65.
15. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 2002; 77:936-44.
16. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6.
17. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al., Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178:1748-58.
18. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105:2893-8.
19. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730-7.
20. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al., Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671-4.
21. Arai T, Yamashita S, Hirano K, Sakai N, Kotani K, Fujioka S, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994; 14 1129-36.
22. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327-32.
23. Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144:2195-200.
24. Tham DM, Martin-McNulty B, Wang Y-x, Wilson DW, Vergona R, Sullivan ME, et al., Angiotensin II is associated with activation of NF-{kappa}B-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11:21-30.
25. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277:42557-62.
26. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78:656-60.
27. Verma S, Li S-H, Wang C-H, Fedak PWM, Li R-K, Weisel RD, et al., Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. 2003; 108:736-40.
28. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156:279-84.
29. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al., Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007; 193:121-8.
30. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296-301.
31. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-63.
32. Patel S, Flyvbjerg A, Kozakova M, Frystyk J, Ibrahim IM, Petrie JR, et al., Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J 2008; 29:386-93.
33. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245:621-5.
34. Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996; 271:9895-7.
35. Kahn BB. Lilly lecture 1995. Glucose transport: Pivotal step in insulin action. Diabetes 1996; 45:1644-54.
36. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999; 10:19-29.
37. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-6.
38. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al., Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278:13740-6.
39. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255:439-47.
40. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26 2442-50.
41. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-7.
42. Nesto RW. Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5:379-87.
43. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al., Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004; 19:694-8.
44. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100.
45. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al., Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673-9.
46. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 393-403.
47. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al., Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003; 289:1799-804.
48. National Institute for Clinical Excellence. Orlistat for the treatment of obesity in adults. Technical Appraisal Guidance No. 22. London, National Institute for Clinical Excellence, 2001.
49. National Institute for Clinical Excellence. The clinical effectiveness and cost effectiveness of sibutramine for obesity. Technical Appraisal Guidance No. 31. London, National Institute for Clinical Excellence, 2001.
50. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; CD004094.
51. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000; 356:2119-25.
52. Padwal R, Majumdar S. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007; 369:71-7.
53. Giugliano G, Nicoletti G, Grella E, Giugliano F, Esposito K, Scuderi N, et al., Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg 2004; 57 190-4.
54. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350 2549-57.
55. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-52.
56. Cholesterol Treatment Trialists' (CTT) Collaborators.Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
57. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286:64-70.
58. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8.
59. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131:48-52.
60. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al., for the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568-76.
61. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism 2006; 55:1283-5.
62. Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M, et al., Fs. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366:1849-61.
63. The BIP Study Group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-7.
64. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al., for the VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162:2597-604.
65. Marx N, Duez H, Fruchart J-C, Staels B. Peroxisome pro-liferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res 2004; 94:1168-78.
66. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366:1279-89.
67. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al., Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:182-8.
68. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, et al., Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:624-30.
69. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115:42-8.
70. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al., the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357:28-38.
71. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356:2522-4.
72. Antiplatelet Trialists' Collaboration.Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 2002; 296:320-31.
73. The Steering Committee of the Physicians' Health Study Research Group. Findings from the aspirin component of the ongoing Physician's Health Study. N Engl J Med 1988; 318:262-4.
74. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al., Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296:313-6.
75. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006; 98:746-50.
76. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793-8.
77. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16:1945-53.
78. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53.
79. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8:585-9.
80. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006; 295 761-75.
81. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-97.
82. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-34.
83. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368 1660-72.
84. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: Updated metaanalysis. Br Med J 2007; 335:1194-9.
85. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, et al., The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63 908-14.
86. National Institute for Health and Clinical Excellence. Rimonabant for the treatment of overweight and obese adults. London, National Institute for Health and Clinical Excellence, 2008.
87. Caro JJ, Stillman IO, Danel A, Getsios D, McEwan P. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007; 10:239-54.